Biotech advisory with a pharma and investor perspective
I help biotech founders and therapeutics companies look at their asset through the eyes of pharma and investors, and turn it into a fundable, partnerable business. From the first corporate conversation to deal execution.
Services
Pharma and investors pass on most assets not because the science is weak, but because the asset isn’t framed around how they decide. I apply these critical criteria based on my expertise and experience as Head External Innovation Technologies, Scientific Competitive Insights and Externalization at Merck KGaA, as Venture Partner at V-Bio Ventures and as a serial entrepreneur, spanning the innovation continuum from start-up to investor to buyer side.
1
“How would a pharma company rate our asset?” An assessment run the way a Search & Evaluation team works: pipeline fit, competitive landscape, target product profile and the data gaps that would kill a deal in due diligence. Then I help you open and nurture the right corporate conversations.
2
“We have a company, but not yet a story investors believe.” We build an exit-driven development plan, working backwards from what an acquirer or next-round investor needs to see, and pressure-test it in a mock investment committee.
3
“The asset is there. The deal is not.” From partner mapping and non-confidential materials to term sheet structure and negotiation, shaped by first-hand experience on the buyer’s side of the table.
4
“We need senior leadership now, not in six months.” Hands-on interim leadership through a critical phase, or a sparring partner for your executive team as the company scales.
Each service stands on its own. Start wherever your most critical gap is.
Why FALCENBERG NBC
01
A strong scientific background paired with a global leadership mindset, bridging the language of the lab and the boardroom.
02
Hands-on company creation as a serial entrepreneur with three companies founded.
03
Trained as a venture capitalist, active Venture Partner, with a strong VC network at partner level.
04
Six years in a leading big-pharma role, shaping 10+ deals with up to $5.4bn in deal value.
05
A broad network of industry experts, and access to next-generation AI technology as Co-Founder of Serinyx, bolstered by next-gen AI.
06
Clear communication and a focus on executing the tasks that move your asset forward.
I have searched and evaluated assets for big pharma, supported investments as an investor and built companies from scratch. My clients get all three perspectives before they walk into the room that matters.
My experience spans venture capital, entrepreneurship and big pharma. That lets me handle the specific requirements along the value chain and speak the language of scientists, investors and executive leaders alike, backed by a network that reaches from tech transfer offices to global pharma BD.
Capabilities and network
Testimonials
“Testimonial to follow.”
“Testimonial to follow.”
“Testimonial to follow.”
“Testimonial to follow.”
Send a short note on your asset and your most pressing question. I will get back to you personally.
Get in touch by email